Randomized, double-blind, placebo-controlled, dose-increased clinical trials of dose groups to assess safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics after repeated oral administration of AVI-CO-004 for 10 days to male HIV-infected subjects

Start Date16 Aug 2020

Sponsor / Collaborator

Avixgen, Inc.

KCT0005182 / Not yet recruitingPhase 1

A First-in-Human, Phase 1, Randomized, Multi center, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy of AVI-3307 Cream in Healthy Adult Subjects and Atopic Dermatitis Patients

Start Date03 Aug 2020

Sponsor / Collaborator

Avixgen, Inc.

KCT0005175 / Not yet recruitingPhase 1

A Randomized, Placebo-Controlled, Double-Blind, Phase I Study to Evaluate the Safety and Pharmacokinetics of eye drop AVI-4015 in healthy volunteers

Start Date13 Jul 2020

Sponsor / Collaborator

Avixgen, Inc.

100 Clinical Results associated with Avixgen, Inc.

0 Patents (Medical) associated with Avixgen, Inc.

Literatures (Medical) associated with Avixgen, Inc.

11 Aug 2023·ACS infectious diseases

Identification of a Non-Nucleoside Reverse Transcriptase Inhibitor against Human Immunodeficiency Virus-1.

Article

Author: Yu, Kyung Lee ; Han, Ri ; Kim, Min-Jung ; Lee, Yoonji ; Oh, Kyungsoo ; You, Ji Chang

The HIV-1 infection epidemic remains a global health problem. Current antiretroviral treatments are effective in controlling the progression of a severe infection. However, the emergence of drug resistance requires an urgent identification of new treatment regimes. HIV-1 reverse transcriptase (RTs) has been a successful therapeutic target owing to its high specificity and potent antiviral properties; therefore, it has become an essential component of current HIV-1 standard treatments. This study identified a new HIV-1 RTs inhibitor (Compound #8) that is structurally unique and greatly effective against HIV-1 through chemical library screening and a medicinal chemistry program by analyzing the structure-activity relationship (SAR). Further analysis of molecular docking and mechanisms of action demonstrated that Compound #8 is a novel type of HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with a flexible binding mode. Therefore, it exhibits great therapeutic potential when combined with other existing HIV-1 drugs. Our current studies suggest that Compound #8 is a promising novel scaffold for the development of new HIV-1 treatments.

01 Sep 2022·Osteoarthritis and CartilageQ2 · MEDICINE

Characterization of rhodanine derivatives as potential disease-modifying drugs for experimental mouse osteoarthritis

Q2 · MEDICINE

Article

Author: Chun, J-S ; Shin, Y ; Kim, M-J ; Kwak, J-S ; Kim, S K ; Yang, J ; Choi, J H ; Lee Yu, K ; Lee, Y ; Im, Y J ; Chang You, J ; Kim, H-J

OBJECTIVEThis study was performed to characterize selected rhodanine derivatives as potential preclinical disease-modifying drugs for experimental osteoarthritis (OA) in mice.METHODSThree rhodanine derivatives, designated rhodanine (R)-501, R-502, and R-503, were selected as candidate OA disease-modifying drugs. Their effects were evaluated by intra-articular (IA) injection in OA mouse models induced by DMM (destabilization of the medial meniscus) or adenoviral overexpression in joint tissues of hypoxia-inducible factor (HIF)-2α or zinc importer ZIP8. The regulatory mechanisms impacted by the rhodanine derivatives were examined in primary-culture chondrocytes and fibroblast-like synoviocytes (FLS).RESULTSAll three rhodanine derivatives inhibited OA development caused by DMM or overexpression of HIF-2α or ZIP8. Compared to vehicle-treated group, for example, IA injection of R-501 in DMM-operated mice reduced median OARSI grade from 3.78 (IQR 3.00-5.00) to 1.89 (IQR 0.94-2.00, P = 0.0001). R-502 and R-503 also reduced from 3.67 (IQR 2.11-4.56) to 2.00 (IQR 1.00-2.00, P = 0.0030) and 2.00 (IQR 1.83-2.67, P = 0.0378), respectively. Mechanistically, the rhodanine derivatives inhibited the nuclear localization and transcriptional activity of HIF-2α in chondrocytes and FLS. They did not bind to Zn²⁺ or modulate Zn²⁺ homeostasis in chondrocytes or FLS; instead, they inhibited the nuclear localization and transcriptional activity of the Zn²⁺-dependent transcription factor, MTF1. HIF-2α, ZIP8, and interleukin-1β could upregulate matrix-degrading enzymes in chondrocytes and FLS, and the rhodanine derivatives inhibited these effects.CONCLUSIONIA administration of rhodanine derivatives significantly reduced OA pathogenesis in various mouse models, demonstrating that these derivatives have disease-modifying therapeutic potential against OA pathogenesis.

14 Sep 2021·Translational Vision Science & TechnologyQ3 · MEDICINE

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models

Q3 · MEDICINE

ArticleOA

Author: You, Ji Chang ; Baek, Yi-Yong ; Go, Hyeon-Kyu ; Sung, Bokyung ; Choi, Jun-Sub ; Kim, Do-Hyung ; Hyon, Joon Young

PurposeDry eye disease (DED) is a multifactorial disorder of the tears and ocular surface accompanied by ocular discomfort, visual disturbance, tear film instability, and ocular surface inflammation. In the present study, we evaluated the efficacy of the tyrosine kinase inhibitor imatinib mesylate for the treatment of DED.MethodsExperimental models of DED were generated in Sprague Dawley rats using a combination of benzalkonium chloride (BAC) with atropine sulfate and in New Zealand White rabbits using BAC. The animals were treated twice daily with eye drops of vehicle, imatinib (0.01%-0.3%), or a positive control (Restasis). The improvement in DED due to imatinib was assessed by staining with fluorescein, lissamine green, impression cytology, and histological analysis. In addition, immunofluorescence staining was performed at the end of the study to evaluate the inflammatory response in the ocular surface.ResultsTopical application of imatinib significantly reduced ocular surface damage compared with vehicle-treated animals. Imatinib restored the morphology and structure of the conjunctival epithelium and reduced the recruitment of immune cells in the corneal epithelium. Furthermore, imatinib significantly reduced the impression cytology score, thus demonstrating that imatinib prevents the loss of goblet cells in DED animal models. The therapeutic efficacy of imatinib was similar to or better than that of cyclosporine treatment.ConclusionsIn this study, we provide an animal in vivo proof of concept of the therapeutic potential of imatinib for the treatment of DED.Translational RelevanceWith this study we show the possibility of developing imatinib as a new ophthalmic drop to treat DED.

News (Medical) associated with Avixgen, Inc.

24 May 2023

·www.prnewswire.com

Avixgen accelerates the progress on new drug pipeline development

- Pipeline development updates on age related macular degeneration, dry eye disease and atopic dermatitis SEOUL, South Korea, May 24, 2023 /PRNewswire/ -- DxVx has released development updates on the pipelines of its recently acquired company, Avixgen. DxVx acquired about 63% stake of Avixgen, which is a new drug development company with strong pipeline in ophthalmic diseases such as age related macular degeneration, dry eye disease as well as atopic dermatitis. Avixgen is currently focusing on dry eye disease which is believed to have the highest potential for commercialization. Avixgen completed Phase 1 clinical trials in Korea through Seoul National University Bundang Hospital, Seoul National University Hospital and Catholic University St. Mary Hospital and plans to conduct Phase 2 clinical trials in Korea and United States simultaneously. Avixgen's main goal for this pipeline is to develop a drug with the long lasting efficacy and reduce side effects comparing to existing drugs. Treatments for age related macular degeneration are being developed as injections and eye drops. The new treatments are expected to have higher efficacy with less side effects owing to the novel mechanism different from existing treatments. In particular, in case of eye drops for age related macular degeneration, anti-angiogenic effects were confirmed at doses 5 to 20 times lower than those of existing drug in rabbit tests and still maintained the efficacy even 28 days after treatment, while the existing drugs' efficacy was completely disappeared. For the injection, Phase 1 clinical trials have been successfully completed at Seoul National University Hospital and Seoul National University Boramae Medical Center. Atopic dermatitis treatment is being developed with a new mechanism to improve inflammatory diseases using non-steroidal substances. It is expected to reduce side effects such as itching and burning feeling, eczema and dermatosis triggered by conventional treatments. Phase 1 clinical trials is scheduled to resume in the first half of next year at Hyundai Asan Meical Center, Sinchon Severance Hospital and H Plus Yangi Hospital An official from Avixgen said "Through participation in national drug development projects and collaboration with its parent company DxVx, we plan to expedite the pipeline development and pursue an IPO in 2025 ultimately" Meanwhile, the global drug market for macular degeneration is expected to reach nearly $18 billion and almost $7 billion for dry eye drug market in 2030 (Source: biospace.com, market.us). SOURCE Dx&Vx

Phase 1Acquisition

100 Deals associated with Avixgen, Inc.

100 Translational Medicine associated with Avixgen, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 28 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AVI-CO-004	Acquired Immunodeficiency Syndrome More	Phase 2
AVI-4015 ( DDR1 )	Xerophthalmia More	Phase 2
Timtraxanib ( VEGFR2 )	Retinal Degeneration More	Phase 1
AVI-6110	-	Preclinical
Claficapavir ( HIV-1 protease )	HIV Infections More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis